Cell：新技术揭示乳腺癌起源与进展，一作已回国加入中国科学院

Core Viewpoint - The article discusses a groundbreaking study on breast cancer that introduces a high-throughput, high-genomic-resolution single-cell DNA and RNA multi-omics technology called wellDR-seq, which helps decode the origins and progression mechanisms of breast cancer [3][5][9]. Group 1 - The research team, led by Nicholas Navin at the MD Anderson Cancer Center, published their findings in the journal Cell, highlighting the first application of wellDR-seq technology [3][5]. - The study analyzed 33,646 single cells from 12 estrogen receptor-positive (ER+) breast cancer patients, identifying cancer ancestral subclones that may represent the origin cells of breast cancer [5][9]. - wellDR-seq allows for the study of gene dosage relationships at the subclonal level, revealing a near-linear correlation in large chromosomal regions and extensive variation at the single-gene level [6][9]. Group 2 - The research identified that 56% of copy number variation segments showed a near-linear correlation with gene expression, providing insights into the complex relationship between copy number and gene expression at the single-cell level [9]. - The study also identified dosage-sensitive and dosage-insensitive genes, including many breast cancer-related genes and incidental copy number variations in non-cancer cells [6][9]. - wellDR-seq is a versatile method applicable not only to breast cancer but also to other cancers and various biomedical fields, enhancing the understanding of cancer development [9].